Aroda VR, Bauer R, Hertz CL, et al. Efficacy and safety of oral semaglutide by baseline age in the PIONEER clinical trial program. Diabetes. 2020;69(Suppl 1): Abstract 932-P.
Aroda AR, Frenkel O, Frias JP, et al. Greater reductions in HbA1c and body weight with once-weekly semaglutide vs. comparators across baseline BMI subgroups: a post hoc analysis of SUSTAIN 1-5 and 7-10. Diabetes. 2020;69(Suppl 1): Abstract 933-P.
Clegg LE, Van Der Aart A, Penland RC, et al. Once-weekly exenatide effects on eGFR Slope and UACR as a function of baseline UACR: An EXSCEL trial post hoc analysis. Diabetes. 2020;69(Suppl 1): Abstract 958-P.
Cukierman-Yaffe T, Gerstein HC, Colhoun HM, et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol. 2020:19;582-590.
DeSouza C, Amod A, Kallenbach K, et al. Efficacy of oral semaglutide according to race: an exploratory subgroup analysis of the PIONEER trial program. Diabetes. 2020;69(Suppl 1): Abstract 930-P.
DeSouza , Kirk AR, Mangla KK, et al. Optimal treatment intensification for glycemic control in patients with T2D on two oral agents: real-world comparison of GLP-1, OADs, and insulin. Diabetes. 2020;69(Suppl 1): Abstract 931-P.
Hartman ML, Sanyal AJ, Loomba R, et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care. 2020;43:1352-1355.
Kelly AS, Auerbach P, Barrientos-Perez M, et al; the NN8022-4180 Trial Investigators. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382:2117-2128.
Unger J, Kaltoft M, Kolhe D, et al. LIRA-PRIME: a randomized trial in primary care settings of liraglutide versus OAD for glycemic control in patients with type 2 diabetes not in control on metformin. Diabetes. 2020;69(Suppl 1): Abstract 922-P.
Wang X, Zhang Q, Guan M, et al. Exenatide and renal outcomes in patients with type 2 diabetes and diabetic kidney disease: a multicenter, randomized, parallel study. Diabetes. 2020;69(Suppl 1): Abstract 26-LB.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Filip K. Knop, MD, PhD

Professor of Endocrinology
Head, Center for Clinical Metabolic Research
Gentofte Hospital
University of Copenhagen
Copenhagen, Denmark

Disclosures

Disclosure: Filip K. Knop , MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Carmot Therapeutics; Eli Lilly and Company; Merck & Co., Inc.; Mundipharma; Novo Nordisk, Sanofi; Zealand Pharma
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Lupin; MedImmune Inc.; Merck & Co., Inc.; Mundipharma; Norgine; Novo Nordisk; Sanofi; Zeland Pharma
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Gubra; Novo Nordisk; Sanofi; Zealand Pharma
Other: Antag Therapeutics ApS

Subodh Verma MD, PhD, FRCSC, FAHA

Cardiac Surgeon, St. Michael’s Hospital
Unity Health Toronto
Scientist, Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute of Unity Health Toronto
Professor of Surgery and Pharmacology & Toxicology
University of Toronto
Toronto, Ontario, Canada
Canada Research Chair in Cardiovascular Surgery

Disclosures

Disclosure: Subodh Verma, MD, PhD, FRCSC, FAHA, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; EOCI; HLS Therapeutics; Janssen Pharmaceuticals; Merck & Co., Inc.; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; EOCI; HLS Therapeutics; Janssen Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi; Sun Pharmaceuticals; Toronto Knowledge Translation Working Group
Received grants for clinical research from: Amarin Corporation plc; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; HLS Therapeutics; Janssen Pharmaceuticals; Merck & Co., Inc.

Editor

Philippa M. Berman, BA(Hons), MBBS

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Philippa M. Berman, BA(Hons), MBBS, has disclosed no relevant financial relationships.

Content Reviewer

Anjali Mehra, MD

Lead Medical Education Director

Disclosures

Disclosure: Anjali Mehra, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CPD

A Digest of Latest Clinical Data With GLP-1 Receptor Agonists

Authors: Filip K. Knop, MD PhD; Subodh Verma MD, PhD, FRCSC, FAHA
CPD Released: 7/10/2020
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 7/10/2021

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US and non-UK diabetologists, endocrinologists, cardiologists, and primary care physicians.

The goal of this activity is to increase physician awareness of key clinical study results with long-acting glucagon-like peptide 1 (GLP-1) receptor agonists.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Recent clinical study results with long-acting GLP-1 receptor agonists

Disclosures

Faculty

Filip K. Knop, MD, PhD

Professor of Endocrinology
Head, Center for Clinical Metabolic Research
Gentofte Hospital
University of Copenhagen
Copenhagen, Denmark

Disclosures

Disclosure: Filip K. Knop , MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Carmot Therapeutics; Eli Lilly and Company; Merck & Co., Inc.; Mundipharma; Novo Nordisk, Sanofi; Zealand Pharma
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Lupin; MedImmune Inc.; Merck & Co., Inc.; Mundipharma; Norgine; Novo Nordisk; Sanofi; Zeland Pharma
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Gubra; Novo Nordisk; Sanofi; Zealand Pharma
Other: Antag Therapeutics ApS

Subodh Verma MD, PhD, FRCSC, FAHA

Cardiac Surgeon, St. Michael’s Hospital
Unity Health Toronto
Scientist, Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute of Unity Health Toronto
Professor of Surgery and Pharmacology & Toxicology
University of Toronto
Toronto, Ontario, Canada
Canada Research Chair in Cardiovascular Surgery

Disclosures

Disclosure: Subodh Verma, MD, PhD, FRCSC, FAHA, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; EOCI; HLS Therapeutics; Janssen Pharmaceuticals; Merck & Co., Inc.; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; EOCI; HLS Therapeutics; Janssen Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi; Sun Pharmaceuticals; Toronto Knowledge Translation Working Group
Received grants for clinical research from: Amarin Corporation plc; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; HLS Therapeutics; Janssen Pharmaceuticals; Merck & Co., Inc.

Editor

Philippa M. Berman, BA(Hons), MBBS

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Philippa M. Berman, BA(Hons), MBBS, has disclosed no relevant financial relationships.

Content Reviewer

Anjali Mehra, MD

Lead Medical Education Director

Disclosures

Disclosure: Anjali Mehra, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.25 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

A Digest of Latest Clinical Data With GLP-1 Receptor Agonists

Authors: Filip K. Knop, MD PhD; Subodh Verma MD, PhD, FRCSC, FAHAFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CPD Released: 7/10/2020

Valid for credit through: 7/10/2021

processing....

ADA = American Diabetes Association
AE = adverse event
ALT = alanine aminotransferase (ALT)
AST = aspartate aminotransferase
BMI = body mass index
DKD = diabetic kidney disease
DPP-4 = dipeptidyl peptidase 4
DSST = Digit Symbol Substitution Test
eGFR = estimated glomerular filtration rate
GFR = glomerular filtration rate
GI = gastrointestinal
GIP = glucose-dependent insulinotropic polypeptide
GLP-1 = glucagon-like peptide 1
K-18 = keratin-18
MACE = major adverse cardiac events
MoCA = Montreal Cognitive Assessment
OAD = oral antidiabetic drug
PBO = placebo
Pro-C3 = procollagen III
RA = receptor agonist
SD = standard deviation
SGLT-2 = sodium-glucose co-transporter-2
SU = sulfonylurea
T2D = type 2 diabetes
TZD = thiazolidinedione
UACR = urinary albumin-creatinine ratio